ReviewDrugs2007
Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature.European journal of medical research · 2009Pooled it
- The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.BMC nephrology · 2009Trial
- Association between serum vitamin D levels and cardiovascular disease risk in patients with hyperuricemia: A cross-sectional study.PloS one · 2026Article
- Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.European journal of clinical pharmacology · 2024Article
- Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis.Experimental and therapeutic medicine · 2020Article
- Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure.British journal of pharmacology · 2020Article
- Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact.International journal of molecular sciences · 2018Review
- Calcitriol Prevents Cardiovascular Repercussions in Puromycin Aminonucleoside-Induced Nephrotic Syndrome.BioMed research international · 2018Article
- Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study).International journal of molecular sciences · 2017Article
- Article
- Inhibitor effect of paricalcitol in rat model of pentylenetetrazol-induced seizures.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
- Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway.International journal of molecular medicine · 2016Article
- Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Mediators of inflammation · 2014Article
- The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.Clinical interventions in aging · 2013Review
- The immunoregulatory function of vitamin D: implications in chronic kidney disease.Nature reviews. Nephrology · 2012Review
- Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study.Diabetes care · 2012Article
- Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes.Heart failure reviews · 2012Review
- Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.Kidney international · 2009Article
- The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism.NDT plus · 2009Article
- Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Nature clinical practice. Nephrology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 'classical' effects of vitamin D receptor activator or agonist (VDRA) therapy for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease primarily involves suppressive effects on the parathyroid gland, and regulation of calcium and phosphorus absorption in the intestine and mobilisation in bone. Observational studies in haemodialysis patients report improved cardiovascular and all-cause survival among those receiving VDRA therapy compared with those not on VDRA therapy. Among VDRAs, the selective VDRA paricalcitol has been associated with greater survival than nonselective VDRAs, such as calcitriol (1,25-dihydroxyvitamin D(3)). The survival benefits of paricalcitol appear to be linked, at least in part, to 'nonclassical' actions of VDRAs, possibly through VDRA-mediated modulation of gene expression. In cardiovascular tissues, VDRAs are reported to have beneficial effects such as anti-inflammatory and antithrombotic effects, inhibition of vascular smooth muscle cell proliferation, inhibition of vascular calcification and stiffening, and regression of left ventricular hypertrophy. VDRAs are also reported to negatively regulate the renin-angiotensin system, which plays a key role in hypertension, myocardial infarction and stroke. The selective VDRAs, paricalcitol and maxacalcitol, are associated with direct protective effects on glomerular architecture and antiproteinuric effects in response to renal damage. Paricalcitol regulates several cardiovascular and renal parameters more favourably than nonselective VDRAs. Complex nonclassical effects, which are not clearly understood, possibly contribute to the improved survival seen with VDRAs, especially paricalcitol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.